Mirum Pharmaceuticals, Inc. (MIRM) Misses Q4 EPS by 155c

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q4 EPS of ($1.85), $1.55 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $99.41 million versus the consensus estimate of $95.4 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• MakeMyTrip (MMYT) PT Raised to $84 at Goldman Sachs
• FDA approves AbbVie's Skyrizi for children with psoriatic disease